The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874].
V. Chiarion-Sileni
Consultant or Advisory Role - Schering-Plough
M. Guida
No relevant relationships to disclose
A. Romanini
No relevant relationships to disclose
R. Ridolfi
No relevant relationships to disclose
M. Mandala
Consultant or Advisory Role - Schering-Plough
P. Del Bianco
No relevant relationships to disclose
B. Silvestri
No relevant relationships to disclose
M. Medici
No relevant relationships to disclose
M. Michiara
No relevant relationships to disclose
M. Dalla Palma
No relevant relationships to disclose
O. Puccetti
No relevant relationships to disclose
J. Pigozzo
No relevant relationships to disclose
F. Laveder
No relevant relationships to disclose
G. L. De Salvo
Research Funding - Italian Melanoma Intergroup